Agosto 2021: The Food and Drug Administration approved idecabtagene vicleucel (Abecma, Bristol Myers Squibb) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first cell-based gene therapy for multiple myeloma that has been approved by the FDA.
Ang Idecabtagene vicleucel ay isang genetically engineered autologous chimeric antigen receptor (CAR) T-cell na paggamot na tina-target ang B-cell maturation antigen (BCMA). Ang bawat dosis ay iniakma sa sariling mga T-cell ng pasyente, na aani, binago ng genetiko, at pagkatapos ay muling ipinakilala sa pasyente.
In a multicenter research, 127 patients with relapsed and refractory maramihang myeloma who had undergone at least three prior lines of antimyeloma therapy were evaluated for safety and efficacy; 88 percent had received four or more prior lines of therapies. The efficacy of idecabtagene vicleucel at doses ranging from 300 to 460 x 106 CAR-positive T cells was studied in 100 individuals. The overall response rate (ORR), complete response (CR) rate, and duration of response (DOR) were calculated using the International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma by an independent response committee.
Ang ORR ay 72 porsyento (95 porsyento CI: 62 porsyento, 81 porsyento), na may 28 porsyento na CR rate (95 porsyento CI 19 porsyento, 38 porsyento). Isang kabuuan ng 65 porsyento ng mga pasyente na nakakuha ng CR ay nanatili dito nang hindi bababa sa isang taon.
Isang nakakahon na babala para sa cytokine release syndrome (CRS), neurologic toxicities, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, and persistent cytopenias is included on the idecabtagene vicleucel label. CRS, infections, exhaustion, musculoskeletal pain, and hypogammaglobulinemia are the most prevalent side effects of idecabtagene vicleucel.
Idecabtagene vicleucel has a risk evaluation and mitigation plan that requires healthcare facilities dispensing the medicine to be specially certified in recognising and managing CRS and nervous system toxicities. The FDA is ordering the company to conduct a post-marketing observational study involving patients treated with idecabtagene vicleucel in order to assess long-term safety.
300 hanggang 460 106 Ang mga cell na positibo sa CAR ay ang iminungkahing saklaw ng dosis para sa idecabtagene vicleucel.
Sanggunian: https://www.fda.gov/
Suriin ang mga detalye dito:
